Paradigm Biopharmaceuticals Limited (PAR) is an Australian biopharmaceutical company focused on repurposing the drug 'pentosan polysulphate sodium' (PPS) for the treatment of bone marrow edema.
Paradigm is targeting addressable markets with the aim to use the shortened development pathway utilising repurposed drugs.